The reaction about anti-hypertensive drugs according to plasma renin-aldosterone states

Year : 2025 | Volume : 15 | 02 | Page : –
    By

    Gwang Choe,

  1. Students, Pyongyang general hospital (Pyongyang, DPRK), Okryu dong No1 Daedonggang district PyongYang city, DPRK, North Korea

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_185950’);});Edit Abstract & Keyword

With recent studies, hypertension has not only simple pathophysiology, thus it can should classify details more about and establishing drug therapy strategies compatible with it is very important methods to improve organ predictive of patients. The purpose of this study is the comparing responsibility of some anti-hypertensive drugs of hypertensive patients according to plasma renin-aldosterone levels that it becomes the background factor of hypertension. We investigated 71 hypertensive men. We included patients whose official hypertensive is 150/100mmHg over but we excluded patients that with secondary hypertensions with target organ disorders, with impossible clear blood pressure measurement because of arrhythmia. We applied DRC (direct renin concentration), PAC (plasma aldosterone concentration) tests per a 14 days in all the members. The tests is performed with blood samples that it can get at rest site with sitting by JL12316 measurement instrument. We administrated 5 drug therapy (hypothiazide 25mg/d, Losartan 50mg/d, amlodipine 5mg/d, hypothiazide and Losartan12.5/50mg, amlodipine and Losartan 5/50mg) to the hypertensive patients. We set 14days that drug therapy duration until drug effect estimation and administrated all drugs between 6 and 8 a.m. After drug therapy, we compare with responsibility of anti-hypertensive drugs according to plasma renin and aldosterone levels. The response to anti-hypertensive drugs of hypertension patients is regulated by plasma aldosterone concentration and the PAC is higher more, the responsibility of anti-hypertensive drugs is lowed.

Keywords: Plasma renin activity (PRA), plasma aldosterone level, low renin hypertension, autonomic aldosterone release, anti-hypertensive therapy.

How to cite this article:
Gwang Choe. The reaction about anti-hypertensive drugs according to plasma renin-aldosterone states. Research and Reviews: A Journal of Pharmacology. 2025; 15(02):-.
How to cite this URL:
Gwang Choe. The reaction about anti-hypertensive drugs according to plasma renin-aldosterone states. Research and Reviews: A Journal of Pharmacology. 2025; 15(02):-. Available from: https://journals.stmjournals.com/rrjop/article=2025/view=0



document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_185950’);});Edit

References

1. Abe K, Irokawa N, Aoyagi H, Seino M, Yasujima M. Low renin hypertension–is it a stage of essential hypertension? Tohoku J Exp Med. 1977 Apr;121(4):347-54. doi: 10.1620/tjem.121.347.
2. Gouli A, Kaltsas G, Tzonou A, Markou A, Androulakis II, Ragkou D, Vamvakidis K, Zografos G, Kontogeorgos G, Chrousos GP, Piaditis G. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest. 2011 Nov;41(11):1227-36. doi: 10.1111/j.1365-2362.2011.02531.x.

3. Giacchetti G, Mulatero P, Mantero F, Veglio F, Boscaro M, Fallo F. Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis. Trends Endocrinol Metab. 2008 Apr;19(3):104-8. doi: 10.1016/j.tem.2008.01.005.
4. Nanba K, Vaidya A, Rainey WE. Aging and Adrenal Aldosterone Production. Hypertension. 2018 Feb;71(2):218-223. doi: 10.1161/HYPERTENSIONAHA.117.10391.
5. Honda M, Izumi Y, Tsuchiya M, Ueda Y, Watanabe H, Inoue T, Shiratsuchi T, Hatano M. A simplified screening test for differentiating primary aldosteronism from essential hypertension with low plasma renin activity. Jpn Circ J. 1980 Sep;44(9):719-25. doi: 10.1253/jcj.44.719
6. Mukhin.N.A. Renin as a target of direct pharmacological block in arterial hypertension.Ter Arkh. 2009:81(8):5-9.
7. Paolo Mulatero ,Andrea Verhovez, Fulvio Morello ,Franco Veglio .Diagnosis and treatment of low-renin hypertension. Clinical Endocrinology 2007;67.324-334.
8. Baudrand R, Guarda FJ, Fardella C, Hundemer G, Brown J, Williams G, Vaidya A. Continuum of Renin-Independent Aldosteronism in Normotension. Hypertension. 2017 May;69(5):950-956. doi: 10.1161/HYPERTENSIONAHA.116.08952.
9. Dluhy RG, Williams GH. Aldosterone–villain or bystander? N Engl J Med. 2004 Jul 1;351(1):8-10. doi: 10.1056/NEJMp048132.
10. Tolagen K. Aldosterone in primary hypertension relationship to plasma renin activity and urinary electrolytes and a comparison with normotensive subjects. Scand J Clin Lab Invest. 1978 Sep;38(5):487-93. doi: 10.1080/00365517809108455.
11. Tolagen K, Karlberg BE. Plasma and urinary aldosterone and their interrelations with blood pressure, plasma renin activity and urinary electrolytes in normotensive subjects. Scand J Clin Lab Invest. 1978 May;38(3):241-7. doi: 10.3109/00365517809108418.
12. Liu Z, Jin L, Zhou W, Zhang C. The spectrum of plasma renin activity and hypertension diseases: Utility, outlook, and suggestions. J Clin Lab Anal. 2022 Nov;36(11):e24738. doi: 10.1002/jcla.24738.

Ahead of Print Subscription Original Research
Volume 15
02
Received 15/02/2025
Accepted 22/03/2025
Published 24/04/2025
Publication Time 68 Days
134

[first_name] [last_name]

My IP

PlumX Metrics